IVAX Diagnostics Confirms That Its Policy is Not to Comment on Unusual Market Activity

MIAMI--(BUSINESS WIRE)-- IVAX Diagnostics, Inc. (NYSE Amex: IVD) today reported that, in light of the unusual market activity in its stock, the NYSE Amex contacted IVAX Diagnostics in accordance with the NYSE Amex’s usual practice. IVAX Diagnostics confirmed that its policy is not to comment on unusual market activity.

About IVAX Diagnostics, Inc.

IVAX Diagnostics, Inc. (www.ivaxdiagnostics.com), headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), and ImmunoVision, Inc. (U.S.).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of IVAX Diagnostics, Inc., including, without limitation, the risks and uncertainties associated with: economic, competitive, political, governmental and other factors affecting IVAX Diagnostics and its operations, markets and products; the success of technological, strategic and business initiatives, including IVAX Diagnostics’ automation strategy and its development and commercial release of the Mago® 4S; IVAX Diagnostics’ ability to receive regulatory approval for the Mago® 4S when expected, or at all; the ability of the Mago® 4S to be available when expected, or at all; the ability of the Mago® 4S to perform as expected; the ability of the Mago® 4 or Mago® 4S to be a source of revenue growth for IVAX Diagnostics; IVAX Diagnostics’ ability to receive financial benefits or achieve improved operating results after the commercial release of the Mago® 4S; the ability of the Mago® 4 or Mago® 4S to be a factor in IVAX Diagnostics’ growth; the ability of the Mago® 4 or Mago® 4S to expand the menu of test kits IVAX Diagnostics offers; IVAX Diagnostics’ ability to successfully market the Mago® 4 or Mago® 4S; IVAX Diagnostics’ customers’ integration of the Mago® 4 or Mago® 4S into their operations; IVAX Diagnostics’ ability to achieve organic growth; IVAX Diagnostics’ ability to identify or consummate acquisitions of businesses or products; IVAX Diagnostics’ ability to integrate acquired businesses or products; IVAX Diagnostics’ ability to generate positive cash flow or otherwise improve its liquidity, whether from existing operations, strategic initiatives or possible future sources of liquidity, including, without limitation, from issuing debt or equity securities, incurring indebtedness or curtailing or reducing operations; the dilutive impact of the issuance of any equity securities which IVAX Diagnostics may issue in the future; constantly changing, and IVAX Diagnostics’ compliance with, governmental regulation; IVAX Diagnostics’ ability to achieve cost advantages from its own manufacture of instrument systems, reagents and test kits; IVAX Diagnostics’ ability to grow beyond the autoimmune and infectious disease markets and to expand into additional diagnostic test sectors; voting control of IVAX Diagnostics’ common stock by ERBA Diagnostics Mannheim GmbH; conflicts of interest with ERBA Diagnostics Mannheim and with our officers, employees and other directors, including, without limitation, our directors that are also executive officers of ERBA Diagnostics Mannheim; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in IVAX Diagnostics’ filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in such filings.



CONTACT:

IVAX Diagnostics, Inc.
Kevin D. Clark, 305-324-2300
CEO, COO & President

KEYWORDS:   United States  North America  Florida

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Infectious Diseases  Medical Devices  FDA

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.